Clinical trials located in

Chojnice

Chojnice city is located in Poland. Currently, 7 clinical trials are being conducted in this city.

Chojnice, a city in northern Poland, boasts a rich history dating back to its founding in 1223. Known for the pivotal Battle of Chojnice during the Thirteen Years’ War in 1454, it has a well-preserved medieval layout. The city’s landmarks include the Gothic St. Mary’s Church and the 14th-century Człuchów Gate, part of its defensive walls. Chojnice also serves as a gateway to the nearby Tuchola Forest, offering a glimpse into Poland’s natural beauty and historical depth.

  • CT-EU-00057161

    Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Testing astegolimab’s effectiveness in chronic obstructive pulmonary disease patients

    A clinical research study is being conducted to examine the efficacy and safety of a novel treatment known as astegolimab in the management of Chronic Obstructive Pulmonary Disease (COPD). The study is particularly focused on individuals with a history of COPD who are either current or former smokers and have experienced frequent exacerbations. Within the scope of this study, astegolimab’s therapeutic potential is being compared to that of a placebo. Participants enrolled in the trial will be administered the study medication at intervals of either every 2 or 4 weeks. Key parameters under evaluation include the frequency of COPD exacerbations, variations in the quality of life of the participants, and changes in lung function over the course of the study. The study aims to contribute valuable data to medical research, particularly in understanding the treatment dynamics of astegolimab in COPD management.

    • Astegolimab
  • Testing the safety and effectiveness of a new drug in adults with atopic dermatitis

    This trial involves the exploration of a new medication, GSK1070806, for adults afflicted with moderate to severe atopic dermatitis, a skin condition characterized by redness and itching. Over a 16-week period, participants are administered either the new medication or a placebo, a substance devoid of therapeutic properties. This double-blind study ensures that neither the participant nor the doctor is aware of the treatment allocation. Parameters assessed include the medication’s efficacy, safety, drug metabolism within the body, and its impact on the disease. An essential metric is the EASI score, reflecting the severity of the skin condition. Additional assessments encompass the evaluation of itchiness levels, pain intensity, and the disease’s effect on sleep and fatigue. Physicians also document any adverse events, which pertain to unexpected medical incidents related to the drug, and ascertain causality.

    • GSK1070806- new potential medication for chronic inflammatory conditions
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine
  • Testing effectiveness of hydrocortisone acetate suppositories for ulcerative colitis

    This trial involves the administration of hydrocortisone acetate suppositories to treat ulcerative colitis in the rectum—an inflammation of the bowel. The study covers adults over 18 years of age. This scientific method ensures unbiased results. Over a span of 28 days, participants will receive a rectal suppository in the morning and evening. The trial aims to measure the safety and effectiveness of the administered drug compared to a placebo. The final goal is to alleviate the symptoms of ulcerative colitis and improve the quality of life for patients suffering from this condition.

    • Hydrocortisone acetate

See more clinical trials in other cities in Poland:

.